To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel

Completed · Phase 3 · Has a placebo group

Conditions studied: Acne Vulgaris

In brief

This is an Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study. The main objective is to evaluate bioequivalence of Test formulation (Clindamycin Phosphate 1.2%/Benzoyl peroxide 5% gel) of Cadila Healthcare with Reference formulation (DUAC® Gel of Stiefel Laboratories)in the ratio of 2:2:1 of Test drug, Reference drug and Placebo respectively. Total study duration will be for a period of 78 days which includes treatment duration of 77 days. 850 subjects will be enrolled (randomized)as per the inclusion and exclusion criteria mentioned in the protocol.

Key facts

Study ID

NCT02005666

Run by

Zydus Lifesciences Limited

People needed

850

Starts

2013-11-01

Expected to finish

2016-09-28

Last updated by the study team

2020-10-14

Who can join

Age: 12 and older, up to 40. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Healthy male or non pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of Acne vulgaris
• On the face, ≥ 25 non-inflammatory lesions (i.e., open and closed comedones) AND ≥ 20 inflammatory lesions (i.e., papules and pustules) AND ≤ 2 nodulocystic lesions (i.e., nodules and cysts).
• Investigator's Global Assessment (IGA) of acne severity grade 2, 3 OR 4
• Willing to refrain from use of all other topical acne medications or antibiotics during the 11 week treatment period.
• If female of childbearing potential, willing to use an acceptable form of birth control during the study.
• Have used the same brand of make-up for a minimum period of 2 weeks prior to randomization, for subjects who use make-up, and agree to not change make-up brands or types during the study.
• Willing to provide written informed consent or assent (HIPAA consent/authorization, as applicable)

You may not qualify if…

• Presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis).
• Patients who have acne conglobata, acne fulminans and secondary acne (e.g.: chloracne and drug induced acne).
• Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris. Well trimmed moustaches are allowed.
• History of hypersensitivity or allergy to benzoyl peroxide or clindamycin and/or any of the study medication ingredients.
• Patients who have a severe or intense irritation on the Face.
• Use within 6 months prior to baseline (Randomization) of oral retinoids (e.g. Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
• Use for less than 3 months prior to baseline (Randomization) of estrogens or oral contraceptives; use of such therapy is allowed if it will remain constant throughout the study.
• Use on the face within 1 month prior to baseline (Randomization) or during the study of: 1) cryodestruction or chemodestruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne surgery, 5) intralesional steroids, or 6) x-ray therapy.
• Use within 1 month prior to baseline (Randomization) of: 1) spironolactone, 2) systemic steroids, 3) systemic antibiotics, 4) systemic treatment for acne vulgaris (other than oral retinoids, which require a 6-month washout), or 5) systemic anti-inflammatory agents.
• Use within 2 weeks prior to baseline (Randomization) of: 1) topical steroids, 2) topical retinoids, 3) topical acne treatments including over-the-counter preparations, 4) topical anti-inflammatory agents, 5) medicated cleansers or 6) topical antibiotics.
• Patients who have had general anesthesia for any reason and patients who have received neuromuscular blocking agents within 14 days prior to study entry (Randomization).
• Concomitant use of facial product containing glycolic or other acids, masks, washes or soaps containing benzoyl peroxide or salicylic acid, non mild cleansers or moisturizers containing retinol, salicylic or α- or β-hydroxy acids.
• Concomitant use of mega-doses of certain vitamins (such as vitamin D and vitamin B12), haloperidol, halogens such as iodide and bromide, lithium, hydantoin and phenobarbital.
• Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 2 weeks or during the study.
• Concomitant use of tanning booths or sunbathing.
• A significant medical history of or are currently immunocompromised
• Have any systemic or dermatologic disease that may affect the evaluation of study results.
• Have a history of regional enteritis, ulcerative colitis, pseudomembranous colitis or antibiotic-associated colitis.
• Subjects with clinically significant unstable medical disorders, life-threatening disease, or current malignancies.
• Subjects who engage in activities that involve excessive or prolonged exposure to sunlight.
• Subjects with History of Alcohol abuse or other drugs of abuse within 2 years prior to Randomization.
• Female subjects who are breast-feeding or planning to become pregnant.
• Subjects who have been treated with an investigational drug or investigational device within a period of 30 days prior to study enrollment.

Where it is running

• Universal BioPharma Research — Dinuba, California, United States
• Research Across America — Santa Ana, California, United States
• Visions Clinical Research — Boynton Beach, Florida, United States
• Dermatology Research Instititue — Coral Gables, Florida, United States
• International Dermatology Research, Inc. — Miami, Florida, United States
• The Indiana Clinical Trials Center — Plainfield, Indiana, United States
• Dermatology Specialists — Louisville, Kentucky, United States
• Minnesota Clinical Study Center — Fridley, Minnesota, United States
• Skin Specialists, PC — Omaha, Nebraska, United States
• Academic Dermatology Associates — Albuquerque, New Mexico, United States
• Yardley Dermatology Associates — Yardley, Pennsylvania, United States
• Discover Research — Bryan, Texas, United States
• Osmania General Hospital — Hyderabad, Andhra Pradesh, India
• Gandhi Hospital, — Hyderabad, Andhra Pradesh, India
• King George Hospital — Visakhapatnam, Andrapradesh, India
• NHL Medical College and VS Hospital — Ahmedabad, Gujarat, India
• AMC-MET Medical College, Sheth LG General Hospital, — Ahmedabad, Gujarat, India
• Sanjeevani Hospital, — Ahmedabad, Gujarat, India
• Dept of Dermatology, Leprosy and STI, Civil Hospital and BJ Medical College, — Ahmedabad, Gujarat, India
• Dept of Dermatology, BYL Nair Hospital and TN medical college, Dr ALNair Road, Mumbai Central, — Mumbai, Gujarat, India
• Department of Dermatology, New Civil Hospital and Government Medical College — Surat, Gujarat, India
• Baroda Medical College — Vadodara, Gujarat, India
• Dept of Dermatology, Bhagawan Mahaveer Jain Hospital Millers Road,Vasanthnagar - — Bangalore, Karnataka, India
• Dept of Dermatology, Kempegowda Institute of Medical Sciences — Bangalore, Karnataka, India
• Sapthagiri Hospital, — Bangalore, Karnataka, India

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.